Evidence map›Paper›PMID 41828044›Full record

ArticleDiagnostics (Basel, Switzerland)2026

Gliflozins in Practice: Real-Life Use of Dapagliflozin and Empagliflozin in HFrEF Versus Clinical Trial Data.

Massimo Mapelli, Rebecca Caputo, Massimo Valenti, Filippo Maria Rubbo, Elisabetta Salvioni, Irene Mattavelli, Arianna Galotta, Arianna Piotti, Fiorella Puttini, Laura Manfrin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Massimo MapelliCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.ORCID 0000-0001-9985-7407
Rebecca CaputoCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.ORCID 0009-0009-8777-6699
Massimo ValentiERN GUARD-Heart Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, ASUGI, University of Trieste, 34100 Trieste, Italy.
Filippo Maria RubboERN GUARD-Heart Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, ASUGI, University of Trieste, 34100 Trieste, Italy.ORCID 0009-0006-7940-9811
Elisabetta SalvioniCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.ORCID 0000-0002-8448-7551
Irene MattavelliCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.ORCID 0000-0002-7781-1691
Arianna GalottaCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.
Arianna PiottiCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.
Fiorella PuttiniCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.
Laura ManfrinERN GUARD-Heart Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, ASUGI, University of Trieste, 34100 Trieste, Italy.
Carlo VignatiCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.ORCID 0000-0002-8235-9353
Simona CostantinoCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.
Piergiuseppe AgostoniCentro Cardiologico Monzino, IRCCS, 20138 Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

dapagliflozinempagliflozinheart failurereal-lifeSGLT2i

Identifiers

PMID41828044
PMCPMC12984319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.